.jpg "Analysts")
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Tesaro (NASDAQ: TSRO), Akcea Therapeutics Inc (NASDAQ: AKCA) and Insulet Corp (NASDAQ: PODD) with bullish sentiments.
Tesaro (NASDAQ: TSRO)
Citigroup analyst Robyn Karnauskas maintained a Buy rating on Tesaro (NASDAQ: TSRO) today and set a price target of $100. The company’s shares closed yesterday at $48.36, close to its 52-week low of $48.
According to TipRanks.com, Karnauskas is a 4-star analyst with an average return of 4.4% and a 50.3% success rate. Karnauskas covers the Healthcare sector, focusing on stocks such as Bellicum Pharmaceuticals, Alexion Pharmaceuticals, and Acceleron Pharma.
Currently, the analyst consensus on Tesaro is Moderate Buy and the average price target is $93.27, representing a 92.9% upside.
In a report issued on April 20, Lake Street also maintained a Buy rating on the stock with a $120 price target.
Find more picks by Best Performing Analysts >>
Akcea Therapeutics Inc (NASDAQ: AKCA)
In a report released today, Do Kim from BMO Capital maintained a Buy rating on Akcea Therapeutics Inc (NASDAQ: AKCA), with a price target of $38. The company’s shares closed yesterday at $23.97.
According to TipRanks.com, Kim is a 4-star analyst with an average return of 18.4% and a 55.7% success rate. Kim covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Fate Therapeutics, and Alnylam Pharma.
Akcea Therapeutics Inc has an analyst consensus of Moderate Buy, with a price target consensus of $32.67.
Insulet Corp (NASDAQ: PODD)
BMO Capital analyst Joanne Wuensch maintained a Buy rating on Insulet Corp (NASDAQ: PODD) today and set a price target of $100. The company’s shares closed yesterday at $87.09, close to its 52-week high of $89.63.
According to TipRanks.com, Wuensch is a 4-star analyst with an average return of 8.6% and a 65.9% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as Wright Medical Group, Irhythm Technologies, and Stryker Corporation.
Currently, the analyst consensus on Insulet Corp is Strong Buy and the average price target is $93.09, representing a 6.9% upside.
In a report issued on May 2, Canaccord Genuity also maintained a Buy rating on the stock with a $90 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
